Insights Into Bladder Cancer

Perspectives on the current treatment practices of non–muscle-invasive and muscle-invasive bladder cancer. Insights on the management of metastatic urothelial cancer

Faculty Chair(s)

Petros Grivas, MD, PhD

University of Washington, USA

Look Inside This Report

Download a sample of this report and start discovering the insights

Key Takeaways

  • Community oncologists noted that the genitourinary oncology field is evolving at a rapid pace, challenging their ability to stay current
  • The introduction of checkpoint inhibitors in various stages of bladder cancer therapy is considered the most important recent treatment advance, together with erdafitinib (FGFR2/3 inhibitor) and enfortumab vedotin (antibody-drug conjugate) data
  • Physicians believe pembrolizumab is the checkpoint inhibitor with the most robust data overall in bladder cancer
  • Clinical trials and biomarkers are needed to determine proper sequencing


A moderated roundtable discussion focusing on treatment of bladder cancer

Disease state and data presentations were developed in conjunction with Dr Petros Grivas, a medical expert from the University of Washington

The group of advisors comprised community oncologists from the Southwest

Insights on actual and investigational therapies were obtained in early stage non–muscle- and muscle-invasive disease, as well as advanced metastatic bladder cancer

Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Explore Available and Upcoming Insight Reports

View Reports